Biotherapeutics | search
Click here to view Biotherapeutics news from 60+ newspapers.
Bookmark or Share- Iovance Biotherapeutics Announces Clinical Data in - GlobeNewswireAbout Iovance Biotherapeutics, Inc. Iovance Biotherapeutics , Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients ...
- Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Soars on ... - TipRanksLate in 2023, Arcutis Biotherapeutics ( NASDAQ:ARQT) successfully brought to market a treatment with several applications that have exceeded expectations due to pent-up demand. The stock has soared over 392% in the past six months, with more room for substantial growth. It is a compelling option for growth investors interested in a biotech ...
- What's Going On With Iovance Biotherapeutics Today?Iovance Biotherapeutics, Inc. IOVA stock is trading higher. The company recently announced updated clinical data for treating frontline advanced melanoma.. What Happened: On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented at the 2024 ASCO Annual ...
- Developing a new class of engineered live bacterial ... - NatureLive biotherapeutic products (LBPs) are defined as live organisms designed and developed to treat, cure, or prevent a disease or condition in humans 10. Notably, LBPs exclude vaccines, filterable...
- Sensei stock plunges 46% in wake of Phase 1 dataSensei Biotherapeutics ( NASDAQ: SNSE) shares plunged 46% Friday, the day after the biotech company released data from a Phase 1 dose escalation study of its oncology drug candidate SNS-101 in the ...
More
